TOMI Adopts SteraMist Technology to Enhance CGT Manufacturing Standards
- Technology Adoption: TOMI Environmental Solutions, Inc. announced that a leading Cell and Gene Therapy manufacturer has adopted SteraMist ionized Hydrogen Peroxide technology to enhance its contamination control strategy, ensuring compliance with stringent current Good Manufacturing Practices (cGMP).
- Investment Scale: The client has invested in multiple SteraMist systems for surface treatment and automated room fogging, which not only elevates production efficiency but also enhances customer trust in their products by ensuring the highest safety standards.
- Comprehensive Service: TOMI's iHP Corporate Service team will perform a comprehensive whole-facility fogging service covering all critical areas, including manufacturing suites and quality control labs, ensuring a sterile environment for critical pharmaceutical processes.
- Market Demand: The rapid expansion of Cell and Gene Therapy and 503B compounding drives TOMI to remain at the forefront of providing specialized, scalable solutions tailored to the stringent requirements of these high-growth sectors, addressing future market needs effectively.
Trade with 70% Backtested Accuracy
Analyst Views on TOMZ
About TOMZ
About the author
TOMI Adopts SteraMist Technology to Enhance CGT Manufacturing Standards
- Technology Adoption: TOMI Environmental Solutions, Inc. announced that a leading Cell and Gene Therapy manufacturer has adopted SteraMist ionized Hydrogen Peroxide technology to enhance its contamination control strategy, ensuring compliance with stringent current Good Manufacturing Practices (cGMP).
- Investment Scale: The client has invested in multiple SteraMist systems for surface treatment and automated room fogging, which not only elevates production efficiency but also enhances customer trust in their products by ensuring the highest safety standards.
- Comprehensive Service: TOMI's iHP Corporate Service team will perform a comprehensive whole-facility fogging service covering all critical areas, including manufacturing suites and quality control labs, ensuring a sterile environment for critical pharmaceutical processes.
- Market Demand: The rapid expansion of Cell and Gene Therapy and 503B compounding drives TOMI to remain at the forefront of providing specialized, scalable solutions tailored to the stringent requirements of these high-growth sectors, addressing future market needs effectively.
TOMI Secures $500,000 Contract for SteraMist Integration with Major Biopharma
- Contract Signing: TOMI Environmental Solutions has secured a purchase contract valued at approximately $500,000 with one of the world's leading biopharmaceutical companies to integrate its SteraMist Integrated Systems into critical manufacturing infrastructure, enhancing production efficiency.
- Technology Application: The contract mandates the use of SteraMist iHP technology in the client's sterile manufacturing process, ensuring rapid, residue-free decontamination across two separate areas while meeting stringent biopharmaceutical regulatory requirements.
- Market Demand: Launched in late 2024, the SteraMist Integrated System is designed to meet the escalating industry demand for automated, high-throughput decontamination, with a robust pipeline of orders anticipated throughout 2026 and beyond.
- Strategic Collaboration: TOMI's COO highlighted the increasing opportunities to collaborate with large pharmaceutical organizations, indicating the efficacy of SteraMist technology in meeting rigorous validation and throughput requirements, thereby further solidifying the company's market position in the biopharmaceutical sector.
TOMI Environmental Solutions Advances $3 Million Project Pipeline
- Significant Project Progress: TOMI Environmental Solutions has made substantial advancements in its custom integration pipeline, currently valued at approximately $3 million, indicating strong momentum in the life sciences sector and expected future revenue growth.
- Active Project Count: The company has ten active projects across its SteraMist Integrated System and Custom Engineered System platforms, which not only meet the needs of new and existing customers but also reinforce its market position as a turnkey solution provider in the industry.
- Strategic Partnerships: TOMI's strategic partnerships with major enclosure manufacturers like ESCO Micro and Steelco enable seamless integration of advanced iHP technology into existing systems, addressing market demand for comprehensive decontamination solutions and enhancing the company's market reach.
- Sustained Business Development: Several projects are scheduled for completion before year-end, with additional significant initiatives in final procurement and planning stages, indicating the company's ability to maintain consistent project flow in specialized markets, thereby boosting investor confidence in its future growth trajectory.
TOMI Environmental Solutions, Inc. Announces Q3 2025 Financial Results and Details Growth Strategies
Financial Performance: TOMI Environmental Solutions reported a 95% sequential revenue increase to $2.0 million in Q3 2025, driven by higher equipment purchases and strong BIT™ Solution sales, despite a net loss of $(450,000) for the quarter.
Operational Efficiency: The company maintained a healthy gross profit margin of 61% and reduced operational expenses, while also expanding its international revenue contribution from 20% in Q2 to 36% in Q3.
Product Innovation and Market Expansion: TOMI continues to invest in R&D for its SteraMist® technology, with recent FDA approvals broadening its application potential, and has secured new customer partnerships across various sectors.
Future Outlook: The company is strategically positioned for growth with a strong sales order backlog, plans to expand recurring service contracts, and aims to enhance its international presence while maintaining financial flexibility through new capital initiatives.
TOMI Environmental Solutions, Inc. (TOMZ) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: TOMI Environmental Solutions, Inc. reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of a loss of $0.01, and revenues of $2.12 million, which fell short of expectations by 22.77%.
Stock Performance: The company's shares have declined approximately 22.9% since the start of the year, contrasting with the S&P 500's gain of 14.6%, raising concerns about future stock performance.
Earnings Outlook: The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $3.63 million, with a Zacks Rank of #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Waste Removal Services industry, where TOMI operates, ranks in the top 37% of Zacks industries, suggesting that industry trends could significantly influence TOMI's stock performance moving forward.
Earnings Report for November 14, 2025: QUBT, HIVE, VENU, NXXT, MDV, DFLI, FORA, BEEM, TOMZ, BNZI Released After Market Hours
Earnings Reports Overview: Several companies, including Quantum Computing Inc. (QUBT), HIVE Digital Technologies Ltd (HIVE), and Venu Holding Corporation (VENU), are set to report earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Performance Expectations: QUBT is expected to see a 16.67% increase in earnings per share (EPS) compared to last year, while HIVE anticipates an 83.33% increase. In contrast, companies like Forian Inc. (FORA) and Beam Global (BEEM) are projected to experience significant decreases in EPS.
Price to Earnings Ratios: The Price to Earnings (P/E) ratios for these companies vary widely, with QUBT at -55.72 and HIVE at -61.00, indicating differing growth expectations compared to their industry averages.
Analyst Consensus and Surprises: Many companies, such as Banzai International, Inc. (BNZI) and TOMI Environmental Solutions, Inc. (TOMZ), have faced challenges in meeting analyst expectations, with some reporting significant negative surprises in previous quarters.
TOMI Adopts SteraMist Technology to Enhance CGT Manufacturing Standards
- Technology Adoption: TOMI Environmental Solutions, Inc. announced that a leading Cell and Gene Therapy manufacturer has adopted SteraMist ionized Hydrogen Peroxide technology to enhance its contamination control strategy, ensuring compliance with stringent current Good Manufacturing Practices (cGMP).
- Investment Scale: The client has invested in multiple SteraMist systems for surface treatment and automated room fogging, which not only elevates production efficiency but also enhances customer trust in their products by ensuring the highest safety standards.
- Comprehensive Service: TOMI's iHP Corporate Service team will perform a comprehensive whole-facility fogging service covering all critical areas, including manufacturing suites and quality control labs, ensuring a sterile environment for critical pharmaceutical processes.
- Market Demand: The rapid expansion of Cell and Gene Therapy and 503B compounding drives TOMI to remain at the forefront of providing specialized, scalable solutions tailored to the stringent requirements of these high-growth sectors, addressing future market needs effectively.
TOMI Secures $500,000 Contract for SteraMist Integration with Major Biopharma
- Contract Signing: TOMI Environmental Solutions has secured a purchase contract valued at approximately $500,000 with one of the world's leading biopharmaceutical companies to integrate its SteraMist Integrated Systems into critical manufacturing infrastructure, enhancing production efficiency.
- Technology Application: The contract mandates the use of SteraMist iHP technology in the client's sterile manufacturing process, ensuring rapid, residue-free decontamination across two separate areas while meeting stringent biopharmaceutical regulatory requirements.
- Market Demand: Launched in late 2024, the SteraMist Integrated System is designed to meet the escalating industry demand for automated, high-throughput decontamination, with a robust pipeline of orders anticipated throughout 2026 and beyond.
- Strategic Collaboration: TOMI's COO highlighted the increasing opportunities to collaborate with large pharmaceutical organizations, indicating the efficacy of SteraMist technology in meeting rigorous validation and throughput requirements, thereby further solidifying the company's market position in the biopharmaceutical sector.
TOMI Environmental Solutions Advances $3 Million Project Pipeline
- Significant Project Progress: TOMI Environmental Solutions has made substantial advancements in its custom integration pipeline, currently valued at approximately $3 million, indicating strong momentum in the life sciences sector and expected future revenue growth.
- Active Project Count: The company has ten active projects across its SteraMist Integrated System and Custom Engineered System platforms, which not only meet the needs of new and existing customers but also reinforce its market position as a turnkey solution provider in the industry.
- Strategic Partnerships: TOMI's strategic partnerships with major enclosure manufacturers like ESCO Micro and Steelco enable seamless integration of advanced iHP technology into existing systems, addressing market demand for comprehensive decontamination solutions and enhancing the company's market reach.
- Sustained Business Development: Several projects are scheduled for completion before year-end, with additional significant initiatives in final procurement and planning stages, indicating the company's ability to maintain consistent project flow in specialized markets, thereby boosting investor confidence in its future growth trajectory.
TOMI Environmental Solutions, Inc. Announces Q3 2025 Financial Results and Details Growth Strategies
Financial Performance: TOMI Environmental Solutions reported a 95% sequential revenue increase to $2.0 million in Q3 2025, driven by higher equipment purchases and strong BIT™ Solution sales, despite a net loss of $(450,000) for the quarter.
Operational Efficiency: The company maintained a healthy gross profit margin of 61% and reduced operational expenses, while also expanding its international revenue contribution from 20% in Q2 to 36% in Q3.
Product Innovation and Market Expansion: TOMI continues to invest in R&D for its SteraMist® technology, with recent FDA approvals broadening its application potential, and has secured new customer partnerships across various sectors.
Future Outlook: The company is strategically positioned for growth with a strong sales order backlog, plans to expand recurring service contracts, and aims to enhance its international presence while maintaining financial flexibility through new capital initiatives.
TOMI Environmental Solutions, Inc. (TOMZ) Announces Q3 Loss and Falls Short of Revenue Projections
Quarterly Performance: TOMI Environmental Solutions, Inc. reported a quarterly loss of $0.02 per share, missing the Zacks Consensus Estimate of a loss of $0.01, and revenues of $2.12 million, which fell short of expectations by 22.77%.
Stock Performance: The company's shares have declined approximately 22.9% since the start of the year, contrasting with the S&P 500's gain of 14.6%, raising concerns about future stock performance.
Earnings Outlook: The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $3.63 million, with a Zacks Rank of #3 (Hold), indicating expected performance in line with the market.
Industry Context: The Waste Removal Services industry, where TOMI operates, ranks in the top 37% of Zacks industries, suggesting that industry trends could significantly influence TOMI's stock performance moving forward.
Earnings Report for November 14, 2025: QUBT, HIVE, VENU, NXXT, MDV, DFLI, FORA, BEEM, TOMZ, BNZI Released After Market Hours
Earnings Reports Overview: Several companies, including Quantum Computing Inc. (QUBT), HIVE Digital Technologies Ltd (HIVE), and Venu Holding Corporation (VENU), are set to report earnings for the quarter ending September 30, 2025, with varying forecasts and performance expectations.
Performance Expectations: QUBT is expected to see a 16.67% increase in earnings per share (EPS) compared to last year, while HIVE anticipates an 83.33% increase. In contrast, companies like Forian Inc. (FORA) and Beam Global (BEEM) are projected to experience significant decreases in EPS.
Price to Earnings Ratios: The Price to Earnings (P/E) ratios for these companies vary widely, with QUBT at -55.72 and HIVE at -61.00, indicating differing growth expectations compared to their industry averages.
Analyst Consensus and Surprises: Many companies, such as Banzai International, Inc. (BNZI) and TOMI Environmental Solutions, Inc. (TOMZ), have faced challenges in meeting analyst expectations, with some reporting significant negative surprises in previous quarters.
